IL160845A0 - Linked biaryl compounds - Google Patents
Linked biaryl compoundsInfo
- Publication number
- IL160845A0 IL160845A0 IL16084502A IL16084502A IL160845A0 IL 160845 A0 IL160845 A0 IL 160845A0 IL 16084502 A IL16084502 A IL 16084502A IL 16084502 A IL16084502 A IL 16084502A IL 160845 A0 IL160845 A0 IL 160845A0
- Authority
- IL
- Israel
- Prior art keywords
- biaryl compounds
- linked biaryl
- linked
- compounds
- biaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32255601P | 2001-09-14 | 2001-09-14 | |
US33543401P | 2001-11-30 | 2001-11-30 | |
US37862702P | 2002-05-07 | 2002-05-07 | |
US38683302P | 2002-06-06 | 2002-06-06 | |
PCT/US2002/029232 WO2003024395A2 (en) | 2001-09-14 | 2002-09-13 | Linked biaryl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160845A0 true IL160845A0 (en) | 2004-08-31 |
Family
ID=27502245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16084502A IL160845A0 (en) | 2001-09-14 | 2002-09-13 | Linked biaryl compounds |
Country Status (13)
Country | Link |
---|---|
US (2) | US6869975B2 (xx) |
EP (1) | EP1435946B8 (xx) |
JP (1) | JP4269052B2 (xx) |
KR (1) | KR20040063897A (xx) |
CN (1) | CN1585638A (xx) |
AU (1) | AU2002336532C1 (xx) |
BR (1) | BR0212512A (xx) |
CA (1) | CA2460313C (xx) |
ES (1) | ES2443642T3 (xx) |
IL (1) | IL160845A0 (xx) |
MX (1) | MXPA04002330A (xx) |
NZ (1) | NZ531917A (xx) |
WO (1) | WO2003024395A2 (xx) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
EP1435946B8 (en) | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
WO2003078448A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
US20060258683A1 (en) * | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
EP1661879A4 (en) * | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
ATE486055T1 (de) * | 2004-05-05 | 2010-11-15 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
US20110039841A1 (en) * | 2004-05-05 | 2011-02-17 | Novo Nordisk A/S | Novel compounds, their preparation and use |
JP4981662B2 (ja) * | 2004-05-05 | 2012-07-25 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規の化合物、その製法と使用 |
AU2005272786B2 (en) * | 2004-08-12 | 2011-12-22 | Amgen Inc. | Bisaryl-sulfonamides |
EP1650183A1 (en) * | 2004-10-21 | 2006-04-26 | Cellzome Ag | (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy |
JP2008521829A (ja) * | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
AU2005311826A1 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as PPAR active compounds |
FR2880886B1 (fr) * | 2005-01-14 | 2007-04-06 | Merck Sante Soc Par Actions Si | Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
CA2594860A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
EP1843734A4 (en) * | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
DE102005020229A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
DE102005020230A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
US20090118337A1 (en) * | 2005-06-03 | 2009-05-07 | Davis Pamela B | Methods and compositions for treating inflammation |
JP5052511B2 (ja) | 2005-06-30 | 2012-10-17 | ハイ ポイント ファーマシューティカルズ,エルエルシー | Pparデルタ活性化因子としてのフェノキシ酢酸 |
WO2007013694A1 (ja) * | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
BRPI0615929A2 (pt) * | 2005-09-07 | 2011-05-31 | Plexxikon Inc | compostos ativos de ppar, composição, kit e uso dos mesmos |
AU2006287521A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
EP1931658A2 (en) * | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
NZ568488A (en) | 2005-12-22 | 2011-07-29 | High Point Pharmaceuticals Llc | Phenoxy acetic acids as PPAR delta activators |
ES2614090T3 (es) | 2005-12-29 | 2017-05-29 | Celtaxsys, Inc. | Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa |
US7943612B2 (en) * | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
WO2008147445A2 (en) * | 2006-11-09 | 2008-12-04 | University Of Maryland, Baltimore | Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent |
PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
WO2009078981A2 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CN102812000A (zh) * | 2010-01-06 | 2012-12-05 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
CN105001219A (zh) | 2011-02-25 | 2015-10-28 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
WO2014152518A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
RU2696559C2 (ru) | 2013-03-14 | 2019-08-05 | Селтакссис, Инк. | Ингибиторы лейкотриен а4-гидролазы |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
EP3043789B1 (en) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
US11267795B2 (en) | 2020-07-22 | 2022-03-08 | Reneo Pharmaceuticals, Inc. | Crystalline PPAR-delta agonist |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3038934A (en) * | 1959-03-17 | 1962-06-12 | Smith Kline French Lab | Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids |
US4443536A (en) * | 1981-08-25 | 1984-04-17 | Eastman Kodak Company | Nondiffusible photographic couplers and photographic elements and processes employing same |
US4466902A (en) | 1982-01-31 | 1984-08-21 | Ipposha Oil Industries, Co., Ltd. | Rust inhibitor |
EP0359169B1 (en) * | 1988-09-14 | 1995-07-26 | Eastman Kodak Company | Photographic recording material comprising magenta coupler and a chalcogenazolium salt |
JPH10502256A (ja) | 1994-07-01 | 1998-03-03 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物のペルオキシソーム増殖物質活性化受容体およびその使用 |
US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
ATE245622T1 (de) | 1996-02-02 | 2003-08-15 | Merck & Co Inc | Antidiabetische mittel |
EP0904079B1 (en) | 1996-02-02 | 2004-03-24 | Merck & Co., Inc. | Antidiabetic agents |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
US5859051A (en) | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
EP0882029B1 (en) | 1996-02-02 | 2003-04-02 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
US6090839A (en) | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
CA2285553A1 (en) * | 1997-03-27 | 1998-10-08 | Taisho Pharmaceutical Co., Ltd. | 2-phenoxyaniline derivatives |
JP4427825B2 (ja) | 1997-07-24 | 2010-03-10 | アステラス製薬株式会社 | コレステロール低下作用を有する医薬組成物 |
JP2001527082A (ja) | 1997-12-23 | 2001-12-25 | コモンウエルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | ホウ素系化合物 |
US6583157B2 (en) * | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
JP4253126B2 (ja) * | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
CN1245380C (zh) * | 1998-07-24 | 2006-03-15 | 帝人株式会社 | 邻氨基苯甲酸衍生物 |
AU3507700A (en) | 1999-06-01 | 2000-12-18 | University Of Texas Southwestern Medical Center, The | Method of treating hair loss using diphenylether derivatives |
US6399640B1 (en) | 1999-06-18 | 2002-06-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
DK1192137T3 (da) | 1999-06-30 | 2013-11-11 | Amgen Inc | Forbindelser til modulering af PPAR-gamma aktivitet |
PT1206457E (pt) | 1999-08-27 | 2004-03-31 | Lilly Co Eli | Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars |
ES2215719T3 (es) | 1999-09-08 | 2004-10-16 | Glaxo Group Limited | Antagonista ppar oxazol. |
EP1259494A4 (en) | 2000-02-18 | 2004-09-15 | Merck & Co Inc | ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES |
JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
DK1296967T3 (da) | 2000-06-28 | 2006-10-02 | Amgen Inc | Benzothiazolyl-PPAR-gamma-modulatorer |
WO2002008188A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
WO2002014291A1 (en) | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | PPARδ ACTIVATORS |
GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
GB0024362D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
WO2002070011A2 (en) | 2001-02-02 | 2002-09-12 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
JP4499357B2 (ja) * | 2001-02-14 | 2010-07-07 | カロ・バイオ・アー・ベー | 糖質コルチコイド受容体調節剤 |
US6777442B2 (en) * | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
EP1371650A4 (en) | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS |
AU2002331145B2 (en) * | 2001-08-24 | 2008-07-10 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
EP1435946B8 (en) * | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
MXPA04002679A (es) * | 2001-09-27 | 2004-07-30 | Kyorin Seiyaku Kk | Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos. |
US7230031B2 (en) * | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
-
2002
- 2002-09-13 EP EP02773386.4A patent/EP1435946B8/en not_active Expired - Lifetime
- 2002-09-13 AU AU2002336532A patent/AU2002336532C1/en not_active Ceased
- 2002-09-13 WO PCT/US2002/029232 patent/WO2003024395A2/en active IP Right Grant
- 2002-09-13 NZ NZ531917A patent/NZ531917A/en unknown
- 2002-09-13 US US10/244,063 patent/US6869975B2/en not_active Expired - Fee Related
- 2002-09-13 CN CNA028223241A patent/CN1585638A/zh active Pending
- 2002-09-13 JP JP2003528493A patent/JP4269052B2/ja not_active Expired - Fee Related
- 2002-09-13 BR BR0212512-9A patent/BR0212512A/pt not_active IP Right Cessation
- 2002-09-13 KR KR10-2004-7003851A patent/KR20040063897A/ko not_active Application Discontinuation
- 2002-09-13 CA CA2460313A patent/CA2460313C/en not_active Expired - Fee Related
- 2002-09-13 ES ES02773386.4T patent/ES2443642T3/es not_active Expired - Lifetime
- 2002-09-13 MX MXPA04002330A patent/MXPA04002330A/es active IP Right Grant
- 2002-09-13 IL IL16084502A patent/IL160845A0/xx unknown
-
2004
- 2004-08-20 US US10/939,918 patent/US7645779B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20040063897A (ko) | 2004-07-14 |
ES2443642T3 (es) | 2014-02-20 |
BR0212512A (pt) | 2004-10-26 |
EP1435946A4 (en) | 2006-02-01 |
CN1585638A (zh) | 2005-02-23 |
EP1435946A2 (en) | 2004-07-14 |
AU2002336532B2 (en) | 2007-10-18 |
WO2003024395A2 (en) | 2003-03-27 |
NZ531917A (en) | 2006-01-27 |
US20080161351A1 (en) | 2008-07-03 |
WO2003024395A3 (en) | 2003-12-11 |
CA2460313A1 (en) | 2003-03-27 |
WO2003024395A8 (en) | 2004-01-22 |
JP4269052B2 (ja) | 2009-05-27 |
JP2005508318A (ja) | 2005-03-31 |
US20030149108A1 (en) | 2003-08-07 |
EP1435946B8 (en) | 2013-12-18 |
CA2460313C (en) | 2011-03-08 |
US7645779B2 (en) | 2010-01-12 |
MXPA04002330A (es) | 2005-04-08 |
EP1435946B1 (en) | 2013-11-06 |
AU2002336532C1 (en) | 2008-10-16 |
US6869975B2 (en) | 2005-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160845A0 (en) | Linked biaryl compounds | |
GB0101996D0 (en) | Organtic compounds | |
GB0112324D0 (en) | Compounds | |
GB0102668D0 (en) | Compounds | |
GB0108475D0 (en) | New compounds | |
GB0108102D0 (en) | Compounds | |
GB0119474D0 (en) | Compounds | |
GB0102673D0 (en) | Compounds | |
GB0102665D0 (en) | Compounds | |
GB0119472D0 (en) | Compounds | |
EP1458669A4 (en) | ACTIVE COMPOUNDS ON THE NEUROLOGICAL PLAN | |
GB0115178D0 (en) | Compounds | |
GB0118364D0 (en) | Compounds | |
GB0119473D0 (en) | Compounds | |
GB0108097D0 (en) | Compounds | |
GB0105098D0 (en) | Compounds | |
GB0117780D0 (en) | New compounds | |
HUP0102279D0 (en) | New compounds | |
GB0111184D0 (en) | Compounds | |
GB0104397D0 (en) | Compounds | |
GB0115438D0 (en) | Compounds | |
GB0111760D0 (en) | Compounds | |
GB0111189D0 (en) | Compounds | |
GB0115863D0 (en) | Compounds | |
GB0105737D0 (en) | Compounds |